A Registered Cohort Study on Color Discrimination Deficit Associated With Neurodegenerative Disorders.

Neurodegenerative Disorders Clinical Trial

Official title:

A Registered Observational Cohort Study on Color Discrimination Deficit Associated With Neurodegenerative Disorders.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05639140
• Other study ID #: Cohort-Visual
• Status: Recruiting
• Start date: January 1, 2018
• Est. completion date: July 1, 2025

Study information

• Verified date: November 2022
• Source: Fujian Medical University Union Hospital
• Contact: Xiaodong Pan, Doctor
• Phone: 0591-86218341
• Email: pxd77316[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Color discrimination deficit is a common manifestation of Alzheimer's disease (AD). However, the pathophysiology of this dysfunction remains poorly understood. The aim of the present study was to evaluate color discrimination using the Farnsworth-Munsell 100 hue test in patients with AD and mild cognitive impairment (MCI), compared with age-matched control subjects. As a secondary aim, we evaluated whether the outcomes of these visual tests were associated with cognitive.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: July 1, 2025
• Est. primary completion date: July 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

• All patients underwent extensive clinical examination including thorough neurological and somatic examination by a specialized neurologist or geriatrician and extensive neuropsychological examination by a trained psychologist. AD was diagnosed according to the NINCDS-ADRDA criteria.

Exclusion Criteria:

• We excluded individuals with noncompensated somatic illnesses, a history of a psychiatric disorder, color blindness, ophthalmological pathology, severe cranial trauma, focal neurological signs or magnetic resonance imaging examinations suggestive of cerebrovascular disturbances.

Related Conditions & MeSH terms

• Neurodegenerative Diseases
• Neurodegenerative Disorders

Intervention

Other:
• Data collection
Neuropsychological assessment, FM-1OO, brain MRI, electroencephalogram and biomarker datas will be collected

Locations

Country	Name	City	State
China	Fujian Medical University Union Hospital	Fuzhou	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
Fujian Medical University Union Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	TES	The total error score	Baseline
Primary	MoCA scores	The Montreal Cognitive Assessment (MoCA)	Baseline
Secondary	ACE-III scores	Addenbrooke's Cognitive Examination (ACE) score	Baseline